• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 14, 2015

View Archived Issues

Anacor's atopic dermatitis candidate hits the mark; execs cite blockbuster potential

Shares of Anacor Pharmaceuticals Inc. skyrocketed Monday on much-anticipated top-line data from two pivotal trials testing crisaborole topical ointment 2 percent (formerly AN2728) in atopic dermatitis, with impressive early onset of action and safety data pointing to a potential blockbuster. Read More

Tufts: Vaccine pipeline soaring; global sales could hit $40B by 2020

The vaccine product pipeline has never been fuller, with more than triple the number of candidates in development today than in 2005 and global sales on track to reach $40 billion in five years, according to the July/August Impact Report from the Tufts Center for the Study of Drug Development (CSDD). Read More

New CFDA regs covering surprise inspections effective on Sept. 1

HONG KONG – Regulators in China will start making unannounced inspections at pharmaceutical and medical device companies. "This is the first set of regulations for unannounced inspections in China," said Chao Xu, managing director of Chinese medical device service group Osmunda's Germany branch. Read More

Mutations provide clues for promising, new approach to treat SCLC

LONDON – The first comprehensive genome profiling of small-cell lung cancer (SCLC) has revealed that the disease occurs when both copies of two separate tumor suppressor genes are switched off. Read More

Ohr shares buoyed as eye drops clear vision in macular edema study

Ohr Pharmaceutical Inc. shares (NASDAQ:OHRP) snapped out of a months-long amble, jumping 62.6 percent to $3.69 Monday after a small midstage study showed that its lead candidate, OHR-102 (squalamine lactate ophthalmic solution 0.2 percent) eye drops, helped certain patients with macular edema receiving Lucentis (ranibizumab, Genentech Inc./Roche AG) achieve greater visual acuity gains than patients receiving Lucentis alone. Read More

WHO raps another Indian CRO on data integrity

NEW DELHI – The WHO has rapped yet another Indian clinical research organization (CRO) for "critical lapses and major deviations" during the conduct of clinical trials, bringing the spotlight back to the need for Indian pharma firms and CROs to pull up their socks over stringent adherence to trial protocols. Read More

Regulatory front

The EMA, at the request of Denmark, is reviewing human papillomavirus (HPV) vaccines to clarify their safety profile. Read More

Stock movers

Read More

Other news to note

strong>Astrazeneca plc, of London, said the FDA approved Iressa (gefitinib) tablets, 250 mg once daily, for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test. Read More

Financings

TC Biopharm Ltd., of Edinburgh, Scotland, said it raised £1.18 million (US$1.82 million) in equity and grant funding to treat UK-based patients with melanoma, lung and kidney cancer. Scotland's only female angel group, Investing Women, led the £680,000 investment, with support from Scottish Investment Bank and WH Partnership. Read More

In the clinic

strong>Cleveland Biolabs Inc., of Buffalo, N.Y., reported that a phase I study of CBLB612, a drug in development for oncology indications, including the prevention of chemotherapy-induced myelosuppression, showed that single subcutaneous injections of the drug were generally well tolerated in 56 healthy volunteers. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe